Proteolysis-targeting chimeras as therapeutics and tools for biological discovery

GM Burslem, CM Crews - Cell, 2020 - cell.com
New biological tools provide new techniques to probe fundamental biological processes.
Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which …

Hypoxia and metabolic properties of hematopoietic stem cells

CC Zhang, HA Sadek - Antioxidants & redox signaling, 2014 - liebertpub.com
Significance: The effect of redox signaling on hematopoietic stem cell (HSC) function is not
clearly understood. Recent Advances: A growing body of evidence suggests that adult HSCs …

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

W Fiskus, S Boettcher, N Daver, CP Mill, K Sasaki… - Blood cancer …, 2022 - nature.com
Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …

The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche

T Simsek, F Kocabas, J Zheng, RJ DeBerardinis… - Cell stem cell, 2010 - cell.com
Bone marrow transplantation is the primary therapy for numerous hematopoietic disorders.
The efficiency of bone marrow transplantation depends on the function of long-term …

[HTML][HTML] Densely interconnected transcriptional circuits control cell states in human hematopoiesis

N Novershtern, A Subramanian, LN Lawton, RH Mak… - Cell, 2011 - cell.com
Though many individual transcription factors are known to regulate hematopoietic
differentiation, major aspects of the global architecture of hematopoiesis remain unknown …

EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells

N Riggi, ML Suvà, C De Vito, P Provero… - Genes & …, 2010 - genesdev.cshlp.org
Cancer stem cells (CSCs) display plasticity and self-renewal properties reminiscent of
normal tissue stem cells, but the events responsible for their emergence remain obscure. We …

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

W Fiskus, N Daver, S Boettcher, CP Mill, K Sasaki… - Leukemia, 2022 - nature.com
In MLL1-rearranged AML (MLL1-r), the MLL1 fusion protein (MLLFP) causes dysregulated
expression of HOXA9, MEIS1, PBX3, MEF2C and CDK6 [1, 2]. HOXA9 and its co-factor …

Meis1 regulates the metabolic phenotype and oxidant defense of hematopoietic stem cells

F Kocabas, J Zheng, S Thet… - Blood, The Journal …, 2012 - ashpublications.org
The role of Meis1 in leukemia is well established, but its role in hematopoietic stem cells
(HSCs) remains poorly understood. Previously, we showed that HSCs use glycolytic …

Condensate-Promoting ENL Mutation Drives Tumorigenesis In Vivo Through Dynamic Regulation of Histone Modifications and Gene Expression

Y Liu, Q Li, L Song, C Gong, S Tang… - Cancer …, 2024 - aacrjournals.org
Gain-of-function mutations in the histone acetylation “reader” eleven-nineteen-leukemia
(ENL), found in acute myeloid leukemia (AML) and Wilms tumor, are known to drive …

Meis1 establishes the pre-hemogenic endothelial state prior to Runx1 expression

P Coulombe, G Cole, A Fentiman, JDK Parker… - Nature …, 2023 - nature.com
Hematopoietic stem and progenitor cells (HSPCs) originate from an endothelial-to-
hematopoietic transition (EHT) during embryogenesis. Characterization of early hemogenic …